VAPB and amyotrophic lateral sclerosis type 8: Nevertheless, it is still under debate whether the P56S mutation in VAPB induces the symptoms of ALS8 patients by a loss of function (lost/reduced protein interactions), a toxic gain of function (aggregate formation, protein sequestering), or a dominant negative effect (wild-type VAP recruitment).